Hughes R., Chapple DJ: Cardiovascular and neuromuscular effects of dimethyl tubocurarine in anaesthetized cats and rhesus monkeys. Br J Anaesth48:847-852, 1976
5.
Hughes R., Chapple DJ: Effects of non-depolarizing neuromuscular blocking agents on peripheral autonomic mechanisms in cats. Br J Anaesth48:59-68, 1976
6.
Savarese JJ: The autonomic margins of safety of metocurine and d-tubocurarine in the cat . Anesthesiology50:40-46, 1979
7.
Basta SJ: Modulation of histamine release by neuromuscular-blocking drugs. Curr Opin Anaesthesiol5:572-576, 1992
8.
Dyer J., Warren K., Merlin S., et al: Measurement of plasma histamine: Description of an improved method and normal values. J Allergy Clin Immunol70:82-87, 1982
9.
Moss J., Rosow CE: Histamine release by narcotics and muscle relaxants in humans. Anesthesiology59:330-339, 1983
10.
Basta SJ, Savarese JJ, Ali HH, et al: Histamine-releasing potencies of atracurium, dimethyl-tubocurarine, and tubocurarine. Br J Anaesth55:105S, 1983
11.
Savarese JJ, Ali HH, Basta SJ, et al: The cardiovascular effects of mivacurium chloride (BW B1090U) in patients receiving nitrous oxide-opiate-barbiturate anesthesia. Anesthesiology90:386-394,1989
12.
Savarese JJ , Wastila WB: Current research in relaxant development . Semin Anaesth5:304-311, 1986
13.
Stoops CM, Curtis CA, Kovach DA, et al: Hemodynamic effects of mivacurium chloride administered to patients during oxygen-sufentanil anesthesia for coronary artery bypass grafting or valve replacement. Anesth Analg68:333, 1989
14.
Hatano Y., Arai T., Noda J., et al: Contribution of prostacyclin to d-tubocurarine-induced hypotension in humans. Anesthesiology72:28-32, 1990
15.
Moss J., Rosow CE, Savarese JJ, et al: Role of histamine in the hypotensive action of d-tubocurarine in humans. Anesthesiology55:19-25, 1981
16.
Scott Rpf, Savarese JJ, Basta SJ, et al: Clinical pharmacology of atracurium given in high dose. Br J Anaesth58:834-838, 1986
17.
Basta SJ, Ali HH, Savarese JJ, et al: Clinical pharmacology of atracurium besylate (BW33A): A new non-depolarizing muscle relaxant. Anesth Analg61:723-729, 1982
18.
Basta SJ, Savarese JJ, Ali HH, et al: Clinical pharmacology of doxacurium chloride: A new long-acting nondepolarizing muscle relaxant. Anesthesiology69:478-486, 1988
19.
Murray DJ, Mehta MP, Choi WW, et al: The neuromuscular blocking and cardiovascular effects of doxacurium chloride in patients receiving nitrous oxide narcotic anesthesia. Anesthesiology69:472-477, 1988
20.
Stoops CM, Curtis CA, Kovach DA, et al: Hemodynamic effects of doxacurium chloride in patients receiving oxygen-sufentanil anesthesia for coronary artery bypass or valve replacement . Anesthesiology69:365-370, 1988
21.
Lien CA, Belmont MR, Abalos A., et al: The cardiovascular effects and histamine-releasing properties of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia . Anesthesiology82:1131-1138, 1995
22.
Scott Rpf, Savarese JJ, Basta SJ, et al: Atracurium: Clinical strategies for preventing histamine release and attenuating the hemodynamic response. Anesthesiology61:A287, 1984
23.
Powers D., Simpson K., Morici M., et al: The hemodynamic effects of mivacurium chloride in patients undergoing coronary artery bypass graft during fentanyl/valium anesthesia. Anesthesiology69:A530, 1988
24.
Choi WW, Mehta MP, Murray DJ, et al: Neuromuscular and cardiovascular effects of mivacurium chloride in surgical patients receiving nitrous oxide-narcotic or nitrous oxide-isoflurane anaesthesia. Can J Anaesth36:641-650, 1989
25.
From RP, Pearson KS, Choi WW, et al: Neuromuscular and cardiovascular effects of mivacurium chloride (BW B1090U) during nitrous oxide-fentanyl-thiopentane and nitrous oxide-halothane anaesthesia. Br J Anaesth64:193-198, 1990
26.
Durant NN, Bowman WC, Marshall IG: A comparison of the neuromuscular and autonomic blocking activities of (+)-tubocurarine and its N-methyl and O,O,N-trimethyl analogues. Eur J Pharmacol46:297-302, 1977
27.
Savarese JJ , Ali HH, Antonio RP: The clinical pharmacology of metocurine: Dimethyltubocurarine revisited. Anesthesiology47:277-284, 1977
28.
Matteo RS, Brotherton WP, Nishitateno K., et al: Pharmacodynamics and pharmacokinetics of metocurine in humans: Comparison to d-tubocurarine. Anesthesiology57:183-190,1982
29.
Miller RD, Matteo RS, Benet LZ, Sohn YJ: The pharmacokinetics of tubocurarine in man with and without renal failure . J Pharmacol Exp Ther202:1-7, 1977
30.
Stoelting RK : Hemodynamic effects of dimethyltubocurarine during nitrous oxide-halothane anesthesia. Anesth Analg53:513-515, 1974
31.
Stoelting RK : The hemodynamic effects of pancuronium and d-tubocurarine in anesthetized patients. Anesthesiology36:612-615, 1972
32.
Basta SJ, Savarese JJ, Ali HH, et al: Neuromuscular and cardiovascular effects in patients of BW A938U: A new long-acting neuromuscular blocking agent. Anesthesiology65:A281, 1986
33.
Bowman WC, Rodger IW, Houston J., et al: Structure: action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology69:57-86, 1988
34.
Kopman AF: Gallamine, pancuronium and d-tubocurarine compared: Is onset time related to drug potency?Anesthesiology70:915-520, 1989
35.
Lien CA, Matteo RS, Ornstein E., et al: Neostigmine antagonism of doxacurium or pancuronium blockade under isoflurane. Anesthesiology77:A959, 1992
36.
Emmot RS, Bracey BJ, Goldhill DR, et al: Cardiovascular effects of doxacurium, pancuronium, and vecuronium in anesthetized patients presenting for coronary artery bypass surgery. Br J Anaesth65:480-486, 1990
37.
Ali HH, Savarese JJ, Embree PB, et al: Clinical pharmacology of mivacurium chloride (BW B1090U) infusion: Comparison with vecuronium and atracurium. Br J Anaesth61:541-546, 1988
38.
Engback J., Ostergaard D., Skovgaard LT, Viby-Mogensen J.: Reversal of intense neuromuscular blockade following infusion of atracurium . Anesthesiology72:803-806, 1990
39.
Hosking MP, Lennon RL, Gronert GA: Combined H1and H2-receptor blockade attenuates the cardiovascular effects of high-dose atracurium for rapid sequence endotracheal intubation . Anesth Analg67:1089-1093, 1988
40.
Scott Rpf, Savarese JJ, Basta SJ, et al: Atracurium: Clinical strategies for preventing histamine release and attenuating the hemodynamic response. Br J Anaesth57:550-555, 1985
41.
Belmont MR, Lien CA, Quessy S., et al: The clinical neuromuscular pharmacology of 51 W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. Anesthesiology82:1139-1145, 1995
42.
Fisher DM, Rosen JI: A pharmacokinetic explanation for increasing recovery time following larger or repeated doses of nondepolarizing muscle relaxants. Anesthesia65:286-291, 1986
43.
Lien CA, Pavlin EG, Belmont MR, et al: A two-center study to evaluate cisatracurium (51W89) for tracheal intubation in patient recesing propofol or thiopental anesthesia. Anesthesia53A223. 1995
44.
Schmautz E.Deriaz M.Volleo A.Lienhart A.: Evaluation of 51W89 for endotracheal mtubation in surgical patients during N2O O2 prupofol anesthesia. Anesthesia81:A1081, 1994
45.
Stout RG, Belmont MR, Paviin EG, et al: Evaluation of intubation at 90 and 12 seconds following 51W89 administration. AnesthesizSRA1078, 1994
46.
Kopman A.: Nondepoiarizing relaxants: New concepts and new drugs. J Clin Anessin56 Suppl 1):395-455, 1993
47.
Meretoja OA , Taivainen T.Wirtavouri K.: Pharmacodynamic effects of 51WS9, an isomer of atracurium, in children during halotnane anaesthesia. Br J Anaesth74:6-11, 1995
48.
Brandom BW, Woelfel SKGronert BJ, et al: Effects of 51W89 (cisatracurium in children during halothane nitrous oxide anesthesia. Anesthesiology83:A921, 1995
49.
Ornstein E.Lien CAMatteo RS et al: Pharmacodynamics and pharmacokinetics of 31W89 in geriatric surgical patients. AnesthesiologyS1A1075, 1994
50.
Lien CA, Schmith VD, Belmont MR, et al: Pharmacokinetics of 51W89 in patients receiving nitrous oxide-opioid-barbiturate anesthesia. Anesthesiology83:300-308, 1995
51.
Prielipp RCCoursin DBScuderi PE, et al: Comparison of the infusion requiremems and recovery profiles of vecuronium and cisamcurium 51W89 in intensive care unit patients. Anesth AnalgS1:3-12. 1995
52.
Reich DL, Konstadt SNStanlev TE, et al: A two-center study of the cardiovascular effects of 51W89 in patients with coronary artery disease. Anesth Analg80:S393, 1995
53.
Savarese JJ , Ali HH, Basta SJ et al: The clinical neuromuscular pharmacology of mivacurium chloride (BW B1090U): A short-acting nondepolarizing ester neuromuscular blocking drug. Anesthesiology68:723-732, 1988
54.
Plaud B., Legueau F. Debaene B, et al: Mivacurium neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in man. Anesthesiology77:A908, 1992
55.
Cantineau JP , Parte F.Horns JB, et al: Neuromuscular blocking effect of ORG 9426 on human diaphragm. Anesthesiology75:A785, 1991
56.
Donati F.: Onset of action of relaxants. Can J Anaesth35:S52-S58, 1988
57.
Donati F., Antzaka C., Bevan DR: Potency of pancuronium at the diaphragm and adductor pollicis muscles in humans . Anesthesiology65:1-5, 1986
58.
Donati F., Plaud B., Meistleman D.: Vecuronium neuromuscular blockade at the adductor muscles of the larynx and at the adductor pollicis. Anesthesiology74:833-837, 1991
59.
Plaud B., Meistleman C., Donati F.: Organon 9426 neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in man. Anesthesiology75:A784, 1991
60.
Ali HH, Brull SJ, Witkowski T., et al: Efficacy and safety of divided-dose administration for rapid tracheal intubation. Anesthesiology79:A934, 1993
61.
Stanley JC, Carson IW, Gibson FM, et al: Comparison of the haemodynamic effects of pipecuronium and pancuronium during fentanyl anaesthesia. Acta Anaesthesiol Scand35:262-266, 1991
62.
Upton RA, Nguyen RL, Miller RD, et al: Renal and biliary elimination of vecuronium (ORG NC 45) and pancuronium in rats. Anesth Analg61:313, 1982
63.
Starr NJ, Sethna DH, Estafanoous FG: Bradycardia and asystole following the rapid administration of sufentanil with vecuronium. Anesthesiology64:521, 1986
64.
Bartkowski RR, Witkowski TA, Azad S., et al: Rocuronium onset of action: A comparison with atracurium and vecuronium. Anesth Analg77:574-578, 1993
65.
Vuksanaj D. , Fisher DM: Pharmacokinetics of rocuronium in children aged 4-11 years. Anesthesiology82:1104-1110, 1995
66.
Matteo RS, Ornstein E., Schwartz AE, et al: Pharmacokinetics and pharmacodynamics of rocuronium (Org 9426) in elderly surgical patients. Anesth Analg77:1193-1197, 1993
67.
Khalil M., D'Honneur G., Duvaldestin P., et al: Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology80:1241-1247, 1994
68.
Levy JH, Davis GK, Duggan J., Szlam F.: Determination of the hemodynamics and histamine release of rocuronium (Org 9426) when administered in increased doses under N2O/O2-sufentanil anesthesia. Anesth Analg78:318-321, 1994
69.
McCoy EP, Maddineni VR, Elliott P., et al: Haemodynamic effects of rocuronium during fentanyl anaesthesia: comparison with vecuronium. Can J Anaesth40:703-708, 1993
